Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Anteris Technologies ( (AU:AVR) ) has shared an update.
Anteris Technologies Global Corp. announced the appointment of Gregory Moss and David Roberts to its Board of Directors, enhancing its governance with their extensive experience in legal, compliance, business development, and financial management. These appointments follow the resignation of Dr. Wenyi Gu and are expected to strengthen Anteris’ strategic direction and operational oversight, potentially impacting its market positioning positively.
The most recent analyst rating on (AU:AVR) stock is a Buy with a A$15.00 price target. To see the full list of analyst forecasts on Anteris Technologies stock, see the AU:AVR Stock Forecast page.
More about Anteris Technologies
Anteris Technologies Global Corp. is a global structural heart company focused on designing, developing, and commercializing advanced medical devices to restore healthy heart function. Founded in Australia with a significant presence in Minneapolis, USA, the company is known for its lead product, the DurAVR® Transcatheter Heart Valve (THV), which treats aortic stenosis using biomimetic and anti-calcification technology.
Average Trading Volume: 22,681
Technical Sentiment Signal: Sell
Find detailed analytics on AVR stock on TipRanks’ Stock Analysis page.